Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Neurology, Neurology, Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/9/2019 |
| Start Date: | August 15, 2013 |
| End Date: | November 30, 2021 |
Natural History and Biomarkers of C9ORF72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Background:
- Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis
(ALS) or frontotemporal dementia (FTD). The mutation causes a small piece of DNA to repeat
itself thousands of times. The C9ORF gene mutation mostly occurs in families. In those
families, some persons have ALS and others have FTD. Occasionally the C9ORF gene mutation
occurs in persons without a family history. Researchers want to understand how this gene
causes different diseases. They will study how symptoms caused by the C9ORF gene develop and
change over time. They will measure symptoms that occur in ALS and in FTD. In particular,
they will measure strength, ability to move, thinking, and memory. They will also see if
other tests are associated with progression of disease. These tests, called biomarkers, may
help detect or measure C9ORF72 disease in the future.
Objectives:
- To understand how symptoms change over time in people with mutations in a gene called
C9ORF72, which causes ALS and FTD.
Eligibility:
- Adults over age 18 who have this genetic mutation
Design:
- Participants will have up to 4 in-person visits and 3 telephone interviews over 3 years.
Each in-person visit may take place over several days. They may be either inpatient or
outpatient visits.
- At each visit, participants will undergo a series of brain, language, and behavior
tests. These will include:
- Magnetic resonance imaging (MRI) of the brain. This uses magnets, radio waves, and
computers to produce detailed pictures of the brain.
- Collecting spinal fluid. The clinician will make the participant s back numb and then
insert a needle to collect fluid.
- Blood samples will be taken.
- Participants will be asked to perform several language and movement tests.
- Small skin samples will be taken on one visit
- Between visits, participants will answer questions about their health over the phone 3
times.
- Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis
(ALS) or frontotemporal dementia (FTD). The mutation causes a small piece of DNA to repeat
itself thousands of times. The C9ORF gene mutation mostly occurs in families. In those
families, some persons have ALS and others have FTD. Occasionally the C9ORF gene mutation
occurs in persons without a family history. Researchers want to understand how this gene
causes different diseases. They will study how symptoms caused by the C9ORF gene develop and
change over time. They will measure symptoms that occur in ALS and in FTD. In particular,
they will measure strength, ability to move, thinking, and memory. They will also see if
other tests are associated with progression of disease. These tests, called biomarkers, may
help detect or measure C9ORF72 disease in the future.
Objectives:
- To understand how symptoms change over time in people with mutations in a gene called
C9ORF72, which causes ALS and FTD.
Eligibility:
- Adults over age 18 who have this genetic mutation
Design:
- Participants will have up to 4 in-person visits and 3 telephone interviews over 3 years.
Each in-person visit may take place over several days. They may be either inpatient or
outpatient visits.
- At each visit, participants will undergo a series of brain, language, and behavior
tests. These will include:
- Magnetic resonance imaging (MRI) of the brain. This uses magnets, radio waves, and
computers to produce detailed pictures of the brain.
- Collecting spinal fluid. The clinician will make the participant s back numb and then
insert a needle to collect fluid.
- Between visits, participants will answer questions about their health over the phone 3
times.
Objective
The primary objective of this study is to characterize the natural history of disease in
patients who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD). The secondary objective is to assess
whether candidate biomarkers correlate with disease progression.
Study population
62 persons with a documented repeat expansion in C9ORF72 gene who have ALS, ALS-FTD, or FTD
or who are carriers of the gene mutation and have a symptomatic family member.
Design
Participants will undergo a structured battery of clinical and neuropsychological tests at
enrollment and at three follow-up visits to NIH to assess disease severity. During these
visits, physiological, imaging, blood, and CSF for testing of candidate biomarkers will be
obtained. Between visits to NIH, assessments of functional status and cognition will be
carried out by phone. Participants may be seen earlier than the scheduled follow-up visit or
at home if phone assessments indicate clinical deterioration.
Outcome measures
There will be three primary outcome measures, for changes in three areas of function over the
first six months. The primary measure of the severity of motor clinical function will be the
ALS Functional rating scale-revised (ALSFRS-R). The primary measure of the severity of
cognitive function will be changes in verbal fluency score. The primary measure of the
severity of behavioral dysfunction will be the caregiver assessment of the fronto-behavioral
index (FBI). Secondary clinical outcomes will be the forced vital capacity (FVC) and
survival. The correlation between primary and secondary clinical outcome measures and
candidate biomarkers measures will be analyzed in an exploratory fashion to determine whether
candidate biomarkers are predictive of disease onset or progression.
The primary objective of this study is to characterize the natural history of disease in
patients who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD). The secondary objective is to assess
whether candidate biomarkers correlate with disease progression.
Study population
62 persons with a documented repeat expansion in C9ORF72 gene who have ALS, ALS-FTD, or FTD
or who are carriers of the gene mutation and have a symptomatic family member.
Design
Participants will undergo a structured battery of clinical and neuropsychological tests at
enrollment and at three follow-up visits to NIH to assess disease severity. During these
visits, physiological, imaging, blood, and CSF for testing of candidate biomarkers will be
obtained. Between visits to NIH, assessments of functional status and cognition will be
carried out by phone. Participants may be seen earlier than the scheduled follow-up visit or
at home if phone assessments indicate clinical deterioration.
Outcome measures
There will be three primary outcome measures, for changes in three areas of function over the
first six months. The primary measure of the severity of motor clinical function will be the
ALS Functional rating scale-revised (ALSFRS-R). The primary measure of the severity of
cognitive function will be changes in verbal fluency score. The primary measure of the
severity of behavioral dysfunction will be the caregiver assessment of the fronto-behavioral
index (FBI). Secondary clinical outcomes will be the forced vital capacity (FVC) and
survival. The correlation between primary and secondary clinical outcome measures and
candidate biomarkers measures will be analyzed in an exploratory fashion to determine whether
candidate biomarkers are predictive of disease onset or progression.
- INCLUSION CRITERIA:
Patients will be included if they:
- Are age 18 or older
- Have a confirmed repeat expansion in the C9ORF72 gene
EXCLUSION CRITERIA:
Patients will be excluded if they
- have other major neurological or medical diseases that may cause progressive weakness
or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic
diseases, paraneoplastic syndromes, hereditary diseases, infectious diseases,
peripheral neuropathy or radiculopathy or other significant neurological
abnormalities.
- require daytime ventilator support at the time of study entry
- are unable to travel to NIH at the time of study entry
- are unwilling to have follow-up visits
- are unable to understand or decline to sign the Informed Consent at the time of study
entry. Participants can remain in the study (with DPA consent and participant assent)
if they lose consent capacity.
- have pacemakers or other implanted electrical devices, brain stimulators, dental
implants, aneurysm clips (metal clips on the wall of a large artery), metallic
prostheses (including metal pins and rods, heart valves, and cochlear implants),
permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments
in the eye) that exclude magnetic resonance imaging
- have unstable medical conditions that, in the opinion of the investigators, prevent
safe participation in this study.
- are participating in experimental treatment trials at the time of study entry or plan
such participation within 6 months of entry.
Patients will not be excluded if they are receiving standard care medications for treatment
of ALS and its symptoms, or are participating in non-treatment clinical research studies.
Patients will be permitted to participate in experimental treatment trials after the 6
month follow-up visit.
Patients with pacemakers or other implanted electrical devices, brain stimulators, dental
implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses
(including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner,
implanted delivery pumps, or shrapnel fragments, metal fragments in the eye) will not be
excluded but will not undergo magnetic resonance imaging or transcranial magnetic
stimulation.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 800-411-1222
Click here to add this to my saved trials
